Everything’s warmer this winter in Delhi, even a dengue discussion. For years Navin Khanna has studied dengue and other infections with a quiet purposefulness. As he settles into the cane chair, at the faculty lounge and boots up his MacBook, the academic aloofness of the place recedes. In the 26 years that Khanna has been at the International Centre for Genetic Engineering and Biotechnology (ICGEB), he has developed 26 diagnostic kits; 23 of which are in the market.

“It wasn’t mathematics,” he says, with a dismissive laugh. “India is the epicentre of dengue but we under report it. I have suffered from dengue, it can be fatal.”

Come July every year, dengue affects even the non-infected. A constant fear of the disease at the slightest warming of the body lurks in most households. Not the infection but more so, its detection. Most pathology labs still take anywhere between 48-72 hours to report results, which is a long duration for the disease to either turn fatal or fleece the patient in hurried hospitalisations. The fact that there’s now a Day-1 test which can detect infection and its extent on the very day a person gets a fever is just about reaching patients. Still early days, though.

At ICGEB, Khanna developed this three-in-one test which is the only diagnostics of its kind in the world. And it started with a missive from the late President APJ Abdul Kalam, also a former chief of the Defence Research Development Organisation (DRDO).

‘One more try’

Sometime in 2006, DRDO came knocking on Khanna’s door to check if he worked on dengue. The defense centre in Jhansi was unable to battle the disease and Khanna by then had developed a dozen or so diagnostic kits for various infections. Since he had no readymade technology for dengue, he refused. Then, he received a letter from Kalam. It was basically an S.O.S. Dengue was a national priority; refusal wasn’t an option.

But as soon as Khanna developed the test, he had a dilemma at hand. Anything done for DRDO was a closed affair whereas being at ICGEB meant sharing every tech with 60+ member countries, including Pakistan and Bangladesh. Khanna and team had to give it another try—a completely new technology avoiding infringement on his own patent on the previous test. “We realised just doing a dengue antigen or dengue antibody test won’t be enough. So we developed a three-marker test,” says Khanna, group leader at the Recombinant Gene Products Laboratory.

That’s important in a country like India where you can get dengue several times because there are four types of dengue virus—leading to four serotypes. (Serotypes are a class within an organism based on the antigens they produce.) A person generally recovers from primary dengue unless the virus load is very high.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at support@the-ken.com with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at info@the-ken.com or follow us on Twitter.